Achillion intends to establish strategic collaborations where it believes it can accelerate the development or maximize the value of its drug candidates by utilizing the financial, clinical development, manufacturing and/or commercialization strengths of a leading biotechnology or pharmaceutical company. For more information about business development opportunities, please contact:
Joe Truitt
Achillion Pharmaceuticals, Inc.
203.752.5405
Current Collaborations:
Collaboration with Gilead Sciences, Inc.
In 2004, Achillion entered into a research collaboration and license agreement with Gilead Sciences, Inc. for the development and commercialization of compounds for the treatment of chronic hepatitis which inhibit HCV replication through a novel mechanism of action targeting the NS4A protein. Under the collaboration, research and development activities prior to proof-of-concept are overseen by a research committee comprised of equal numbers of Achillion and Gilead representatives. The joint research committee assigns research and development tasks and agrees upon a budget for the research program.
Achillion received $10.0 million from Gilead Sciences upon the execution of the agreement, consisting of license fees and an equity investment, and could receive up to $157.5 million in development, regulatory and sales milestone payments, assuming the successful simultaneous development of a lead and back-up compound, as well as royalties on net sales of products.
